Clinical Trial Update: A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating the safety, tolerability, efficacy, and drug levels of BMS-986369 (golcadomide) in participants with relapsed or refractory T-cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory T-cell Lymphomas

Drugs mentioned

• BMS-986369 (Golcadomide) (Golcadomide)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Relapsed or Refractory T-cell Lymphomas | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING